This guide provides corporate counsel and international practitioners with comprehensive jurisdiction-by-jurisdiction guidance to digital health laws and regulations around the world.
Patented medicine regulations in Canada can be complex and the review process is fast-paced. In this Top Ten, in-house counsel will learn the essential points of how to prepare for the "Regulations" review. Editor's note: This article was updated to reflect recent developments; a prior version of this article was published on August 6, 2020.
People around the world continue to grapple with the COVID-19 pandemic, the most extreme public health emergency in a century. This Top Ten discusses the public health law framework in the United States and summarizes some recent developments in the law arising from the COVID-19 pandemic.
The Personalized Medicine Coalition (PMC) recently released its annual report on the progress of precision medicine as measured by precision medicine FDA approvals in 2022 (“Report”). As summarized in the Report, 2022 milestones include progress in diagnostics, therapeutics and new treatment modalities that are covered in this resource from Foley and Lardner LLP.
With the pandemic, there came a digital health explosion, with companies working swiftly to bring new technologies to light that would pave the way forward in telehealth and other critical areas. We saw an incredible interest in this space then, but what is the state of digital health now? This resource from Foley & Lardner LLP looks at data from public and private financing markets in the digital health space in 2022, and look forward to what to expect in 2023.
With the health care industry under pressure to improve patient outcomes while controlling costs, artificial intelligence (AI) and machine learning (ML) are quickly becoming indispensable tools. These technologies show promise in supporting decision-making, enhancing the delivery of care, and personalizing medicine. This resource from Foley & Lardner explores opportunities for health care organizations deploying AI-based solutions.
This resource provided by Foley & Lardner LLP covers the DOJ’s announcement on February 6th of their withdrawal of the 2011 Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program (2011 ACO Statement) in addition to two other health care antitrust policy statements.
This resource from Foley and Lardner provides insight into the most prominent trends throughout 2023. These trends are focused on the health care and life sciences sector.
In recent years, companies specializing in artificial intelligence (AI) technologies have been increasingly coveted acquisition targets. Foley & Lardner have provided insight into the AI field transforming our approaches to key issues. Accordingly, it is no surprise that AI has emerged as a prime sector for M&A activity. This guide helps breakdown how to approach risks and rewards in dealing with the rising importance of Artificial Intelligence.
This guide provided by Foley & Lardner summarizes the key elements and requirements contained in the proposed rule. In addition it explains how it differs from the special telemedicine registration rule. Finally, it describes what stakeholders can do to make their voice heard, including by submitting comments to the proposed rule, during these next 30 days.